Events

On Wednesday, February 20, from 5:30 p.m. - 8:30 p.m., Knobbe Martens' San Diego office will be hosting MIT Enterprise Forum and their event, "Hope for Millions: BioFluidica revolutionizes cancer diagnostics."

This program will give you a look into BioFluidica’s next generation diagnostic platform, providing a non-invasive procedure that can be applied to many diseases where there is a need for improved diagnostics. The platform has been validated for six different cancer types, stroke, and infectious diseases. In the cancer field alone, there is a tremendous need to improve diagnostic capabilities.

Better cancer detection, and subsequent personalized treatment, precision medicine, are keys to improve patient treatment and outcomes. Detection of novel biomarkers, such as Circulating Tumor Cells, CTCs, are leading the way to improved diagnostics. In order to improve the survival rate for many cancer diseases, the field of oncology needs better therapies and optimized personalized patient treatment. This will require the evolution of better technologies. BioFluidica is now delivering these new and improved technologies for the analysis of circulating markers, fullfilling the promise of a true liquid biopsy.

Featuring:

Rolf Muller, Ph.D., CEO, BioFluidica

Kim Kamdar, Ph.D., Partner, Domain Associates

Please click here to register for this event.